Beeharry MK, Liu WT, Yan M, Zhu ZG. New blood markers detection technology: A leap in the diagnosis of gastric cancer. World J Gastroenterol 2016; 22(3): 1202-1212 [PMID: 26811658 DOI: 10.3748/wjg.v22.i3.1202]
Corresponding Author of This Article
Wen-Tao Liu, MD, PhD, Key Laboratory of Shanghai Gastric Neoplasms, Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University, 197 Ruijin Road II, Shanghai 200025, China. wt_mygod@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 21, 2016; 22(3): 1202-1212 Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1202
New blood markers detection technology: A leap in the diagnosis of gastric cancer
Maneesh K Beeharry, Wen-Tao Liu, Min Yan, Zheng-Gang Zhu
Maneesh K Beeharry, Wen-Tao Liu, Min Yan, Zheng-Gang Zhu, Key Laboratory of Shanghai Gastric Neoplasms, Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai 200025, China
Author contributions: Beeharry MK performed the literature research, data analysis and wrote the manuscript; Liu WT contributed to the literature research and provided a critical revision of the manuscript; Yan M and Zhu ZG supervised the study and provided a critical revision of the manuscript prior to submission.
Supported by National Natural Science Foundation of China, No. 30872477 and No. 30901729.
Conflict-of-interest statement: The authors of the manuscript hereby declare no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Wen-Tao Liu, MD, PhD, Key Laboratory of Shanghai Gastric Neoplasms, Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University, 197 Ruijin Road II, Shanghai 200025, China. wt_mygod@163.com
Telephone: +86-21-64370045 Fax: +86-21-64314781
Received: April 5, 2015 Peer-review started: April 7, 2015 First decision: September 9, 2015 Revised: September 28, 2015 Accepted: November 24, 2015 Article in press: November 24, 2015 Published online: January 21, 2016
Core Tip
Core tip: Gastric cancer (GC)’s poor prognosis has partly been a result of its late diagnosis due to its asymptomatic and nonspecific symptoms in its early stages. Tremendous advances in the OMICS technology have allowed the development of several methods helping to understand the mechanisms underlying gastric carcinogenesis, resulting in the identification of a large number of molecular targets such as circulating tumor cells, cell free DNA, cell tumor DNA and their sub-molecular components such as miRNA that show great promise as GC biomarkers. In this review, we are underlying the recent breakthroughs about new blood markers technology for GC while scrutinizing their potential clinical use in the pathogenesis, diagnosis and management of GC.
